4.7 Article

Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Oncology

Non-coding RNAs as liquid biopsy biomarkers in cancer

Shusuke Toden et al.

Summary: Non-coding RNAs, previously considered as non-functional, have been found to play a critical role in various cancers and have potential as clinical biomarkers. Among them, microRNAs are extensively studied as liquid biopsy biomarkers. High-throughput sequencing technology allows comprehensive characterization of non-coding RNA expression profiles in different cancers. Technological advancements have also made it possible to identify previously unrecognized biomarkers in cancer patients.

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome

Maria-Alexandra Papadimitriou et al.

Summary: Despite advances in MM therapy, relapse and treatment resistance are still obstacles. Research on miRNAs in MM patients showed miR-181a as a potential biomarker for risk-stratification and prognosis, with overexpression associated with shorter progression and worse survival. Integrating miR-181a with established markers improved risk-stratification and benefit for MM prognosis.

BRITISH JOURNAL OF CANCER (2022)

Article Hematology

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

S. Vincent Rajkumar

Summary: Multiple myeloma is a hematologic malignancy that accounts for approximately 10% of cases. The diagnosis is based on the presence of clonal bone marrow plasma cells and associated symptoms. High-risk patients require stem cell transplantation and may benefit from different treatment regimens.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Review Oncology

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions

Patrick Hagen et al.

Summary: Multiple myeloma is a malignant plasma cell disorder that occurs in late life. Despite the use of various risk stratification systems in clinical practice, there is still a lack of consensus on the definition of high risk disease. Establishing a unified definition of high risk disease is important for guiding treatment approaches and research requirements.

BLOOD CANCER JOURNAL (2022)

Review Cell Biology

Emerging roles of spliceosome in cancer and immunity

Hui Yang et al.

Summary: The spliceosome, while crucial for cell function, can also be implicated in diseases and serve as a target for cancer therapy. Research has shown connections between the spliceosome and immune signaling, leading to immune dysregulation. Furthermore, core spliceosome components have splicing-independent immune functions, adding to their functional diversity.

PROTEIN & CELL (2022)

Article Multidisciplinary Sciences

Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma

Kristin Roseth Aass et al.

Summary: In this study, functional miRNA-mRNA target pairs were identified by analyzing miRNA and mRNA data from primary multiple myeloma cells. The study found that miRNA-mRNA pairs predicted by target-prediction algorithms were negatively correlated, indicating functional miRNA targeting. Furthermore, the study identified several target pairs associated with important processes in multiple myeloma, such as autophagy and protein degradation. These findings provide a knowledge base for further research in the miRNA/multiple myeloma field.

SCIENTIFIC REPORTS (2022)

Article Hematology

Differential RNA splicing as a potentially important driver mechanism in multiple myeloma

Michael A. Bauer et al.

Summary: Disruption of normal RNA splicing patterns plays a major role in the pathogenesis of various diseases, particularly cancer. This study investigates the extent and impact of alternative splicing in multiple myeloma, identifying differentially spliced genes and showing potential implications for MM classification and patient risk stratification.

HAEMATOLOGICA (2021)

Review Biotechnology & Applied Microbiology

Roles of miRNA dysregulation in the pathogenesis of multiple myeloma

Dan Chen et al.

Summary: miRNAs play a critical role in regulating pathological factors involved in the progression of multiple myeloma, including bone marrow microenvironment, methylation, immune regulation, genomic instability, and drug resistance. They also have potential as novel prognostic biomarkers and therapeutic targets.

CANCER GENE THERAPY (2021)

Review Biochemistry & Molecular Biology

Small non-coding RNAs in human cancer: function, clinical utility, and characterization

Zhao Zhang et al.

Summary: Small non-coding RNAs play critical roles in cancer development and have the potential to be biomarkers and therapeutic targets. Recent research has focused on four sncRNA species in cancer and their functional significance, highlighting their potential utility as prognostic and diagnostic biomarkers.

ONCOGENE (2021)

Review Biochemistry & Molecular Biology

Alternative splicing and cancer: a systematic review

Yuanjiao Zhang et al.

Summary: The study systematically describes the abnormal regulation and functions of alternative splicing in tumors, as well as introduces therapeutic strategies targeting splicing catalysis and regulatory proteins. Further research is needed to fully understand the association between alternative splicing and cancer.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Article Multidisciplinary Sciences

U1 snRNP regulates cancer cell migration and invasion in vitro

Jung-Min Oh et al.

NATURE COMMUNICATIONS (2020)

Review Oncology

Small Nucleolar RNAs: Insight Into Their Function in Cancer

Junnan Liang et al.

FRONTIERS IN ONCOLOGY (2019)

Article Biochemistry & Molecular Biology

RNA components of the spliceosome regulate tissue-and cancer-specific alternative splicing

Heidi Dvinge et al.

GENOME RESEARCH (2019)

Review Biochemistry & Molecular Biology

Circulating microRNAs and Their Role in Multiple Myeloma

Cinzia Federico et al.

NON-CODING RNA (2019)

Article Biochemistry & Molecular Biology

Large-scale profiling of microRNAs for The Cancer Genome Atlas

Andy Chu et al.

NUCLEIC ACIDS RESEARCH (2016)

Article Medicine, Research & Experimental

Centrosome associated genes pattern for risk sub-stratification in multiple myeloma

Fedor Kryukov et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2016)

Review Biochemistry & Molecular Biology

The role of MicroRNAs in human cancer

Yong Peng et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)

Review Biochemistry & Molecular Biology

Why should cancer biologists care about tRNAs? tRNA synthesis, mRNA translation and the control of growth

Savraj S. Grewal

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2015)

Article Biochemical Research Methods

HTSeq-a Python framework to work with high-throughput sequencing data

Simon Anders et al.

BIOINFORMATICS (2015)

Article Biotechnology & Applied Microbiology

voom: precision weights unlock linear model analysis tools for RNA-seq read counts

Charity W. Law et al.

GENOME BIOLOGY (2014)

Article Hematology

Improved risk stratification in myeloma using a microRNA-based classifier

Ping Wu et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

Article Biochemical Research Methods

Fast gapped-read alignment with Bowtie 2

Ben Langmead et al.

NATURE METHODS (2012)

Article Biochemistry & Molecular Biology

A distinct class of small RNAs arises from pre-miRNA-proximal regions in a simple chordate

Weiyang Shi et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)

Article Oncology

International staging system for multiple myeloma

PR Greipp et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Review Biochemistry & Molecular Biology

MicroRNAs: Genomics, biogenesis, mechanism, and function

DP Bartel